JP2013502442A5 - - Google Patents

Download PDF

Info

Publication number
JP2013502442A5
JP2013502442A5 JP2012525830A JP2012525830A JP2013502442A5 JP 2013502442 A5 JP2013502442 A5 JP 2013502442A5 JP 2012525830 A JP2012525830 A JP 2012525830A JP 2012525830 A JP2012525830 A JP 2012525830A JP 2013502442 A5 JP2013502442 A5 JP 2013502442A5
Authority
JP
Japan
Prior art keywords
acid
tetrahydroxy
cholan
bile
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012525830A
Other languages
English (en)
Japanese (ja)
Other versions
JP5909774B2 (ja
JP2013502442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2010/001338 external-priority patent/WO2011022838A1/en
Publication of JP2013502442A publication Critical patent/JP2013502442A/ja
Publication of JP2013502442A5 publication Critical patent/JP2013502442A5/ja
Application granted granted Critical
Publication of JP5909774B2 publication Critical patent/JP5909774B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012525830A 2009-08-25 2010-08-25 胆道疾患を治療するためのポリヒドロキシル化胆汁酸 Active JP5909774B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23675009P 2009-08-25 2009-08-25
US61/236,750 2009-08-25
PCT/CA2010/001338 WO2011022838A1 (en) 2009-08-25 2010-08-25 Polyhydroxylated bile acids for treatment of biliary disorders

Publications (3)

Publication Number Publication Date
JP2013502442A JP2013502442A (ja) 2013-01-24
JP2013502442A5 true JP2013502442A5 (cg-RX-API-DMAC7.html) 2013-10-10
JP5909774B2 JP5909774B2 (ja) 2016-04-27

Family

ID=43627124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012525830A Active JP5909774B2 (ja) 2009-08-25 2010-08-25 胆道疾患を治療するためのポリヒドロキシル化胆汁酸

Country Status (7)

Country Link
EP (1) EP2470553B1 (cg-RX-API-DMAC7.html)
JP (1) JP5909774B2 (cg-RX-API-DMAC7.html)
CN (1) CN102712672B (cg-RX-API-DMAC7.html)
AU (1) AU2010286253A1 (cg-RX-API-DMAC7.html)
BR (1) BR112012004284B8 (cg-RX-API-DMAC7.html)
SG (1) SG178562A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011022838A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2758060T (pt) * 2011-09-19 2018-01-24 ETH Zürich Moduladores de ror gama para o tratamento de complicações de diabetes ii
JP6217938B2 (ja) 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
ES2822375T3 (es) 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
WO2014085474A1 (en) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
EP2781217A1 (en) * 2013-03-18 2014-09-24 ETH Zurich ROR gamma modulators
BR112016002268B1 (pt) 2013-08-01 2022-11-01 The Penn State Research Foundation Uso de inibidores do receptor x farnesoide
CN104523703A (zh) * 2014-12-24 2015-04-22 聂飚 一种游离脂肪酸转运蛋白小分子抑制物的应用
US12186329B2 (en) 2018-08-23 2025-01-07 President And Fellows Of Harvard College Compositions and methods related to cholic acid 7-sulfate as a treatment for diabetes
WO2020117945A1 (en) 2018-12-04 2020-06-11 President And Fellows Of Harvard College Synthetic derivatives of cholic acid 7-sulfate and uses thereof
KR102204406B1 (ko) * 2019-01-23 2021-01-18 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물
CN109762043B (zh) * 2019-03-06 2020-07-24 华南理工大学 鹅去氧胆酸及其制备方法
CN120757601A (zh) 2019-05-10 2025-10-10 哈佛大学的校长及成员们 肠道细菌胆汁酸代谢的小分子调节剂
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
CN110548037B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途
CN113024624B (zh) * 2019-12-25 2024-09-10 上海科胜药物研发有限公司 一种去氧胆酸的合成方法
WO2022233398A1 (en) 2021-05-04 2022-11-10 Kostner Pharma Gmbh COMPOUNDS FOR REDUCING LIPOPROTEIN(a)
CN115337312B (zh) * 2022-08-19 2025-06-03 金熊药业(珠海横琴)有限公司 胆酸复合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS632932A (ja) * 1986-06-23 1988-01-07 Teijin Ltd 経鼻投与用粉末状組成物
CA2338457C (en) * 1998-07-24 2009-11-17 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
WO2006116815A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition for the control of cholesterol levels
WO2006116814A1 (en) * 2005-05-02 2006-11-09 Vanadis Bioscience Ltd Composition and uses thereof
CA2716922C (en) * 2008-02-26 2016-06-28 British Columbia Cancer Agency Branch Polyhydroxylated bile acids for treatment of biliary disorders

Similar Documents

Publication Publication Date Title
JP2018507914A5 (cg-RX-API-DMAC7.html)
JP2018030855A5 (cg-RX-API-DMAC7.html)
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
IL272718A (en) 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators
JP2019507781A5 (cg-RX-API-DMAC7.html)
JP2018514534A5 (cg-RX-API-DMAC7.html)
WO2008057420A3 (en) Extended triterpene derivatives
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
WO2007101873A3 (en) Betulonic acid esters and betulinic acid polyalkylene-glycol derivatives for the treatment of viral infection and cancer
NZ586751A (en) Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function
JP2016506391A5 (cg-RX-API-DMAC7.html)
WO2009028457A1 (ja) 非アルコール性脂肪肝炎治療薬
JP2013509411A5 (cg-RX-API-DMAC7.html)
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
JP2016530279A5 (cg-RX-API-DMAC7.html)
CN113164498A (zh) 用于肝病的治疗的组合疗法
JP2011530493A5 (cg-RX-API-DMAC7.html)
JP2021535175A5 (cg-RX-API-DMAC7.html)
JP2012511510A5 (cg-RX-API-DMAC7.html)
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JP2018505218A5 (cg-RX-API-DMAC7.html)
JP2009517411A5 (cg-RX-API-DMAC7.html)
RU2019110779A (ru) Новые схемы введения агонистов fxr
AU2005331734B2 (en) Use of 24-nor-UDCA
Buchanan-Peart et al. Novel therapies in primary biliary cholangitis: what is in the pipeline?